

No: 25./2025/CV-VMD

About: Explaining the fluctuation of over 10% in the business performance on the audited separate financial statements and consolidated financial statements of 2024 compared to 2023

Ha Noi, 31. March 2025

**TO:**           **The State Securities Commission**  
**Ho Chi Minh City Stock Exchange**

Pursuant to the guidance in Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance on guidance on information disclosure on the stock market, Vimedimex Pharmaceutical Joint Stock Company (Vimedimex Company), stock code: VMD, explains the profit fluctuations of 2024 compared to 2023 on the audited Separate Financial Statements and Consolidated Financial Statements as follows:

Content	2024	2023	Difference	% Increase/Decrease
Profit after corporate income tax – Separate Financial Statements	21.721.522.002	19.283.040.429	2.438.481.573	12,65%
Profit after corporate income tax – Consolidated Financial Statements	23.552.656.097	31.189.485.627	-7.636.829.530	-24,49%

**In the Separate Financial Statements:**

Profit after corporate income tax of 2024 in the Separate Financial Report increased by **VND 2,438,481,573**, equivalent to an increase of **12.65%** over the same period in 2023, mainly due to:

- Revenue from sales and service provision activities of 2024 decreased by **VND 2,412,933,357**, equivalent to **2.87%** compared to the same period in 2023..

- Financial operating revenue of 2024 increase by **VND 463,371,183**, equivalent to **2.6%** compared to the same period in 2023.

- However, the company reduced costs of 2024 compared to the same period in 2023: selling expenses decreased by **VND 1.16 billion**, equivalent to **7.75%**, management expenses increased by **VND 4.86 billion**, equivalent to **34.5%**.



**In the Consolidated Financial Statements:**

Profit after corporate income tax of 2024 in the Consolidated Financial Statements decreased by **VND 7,636,829,530**, equivalent to an decrease of **24.49%** over the same period in 2023, mainly due to:

- Revenue from sales and service provision of 2024 decreased by **VND 2,297,292,038,092**, equivalent to **-64.67%** compared to the same period in 2023.

- Financial operating revenue decreased by **VND 6,023,279,201**, equivalent to **44.83%** over the same period in 2023.

- However, the company reduced costs: Selling expenses decreased by **VND 121,365,565,489** equivalent to **58.6%**, management expenses decreased by **VND 15,405,391,081** equivalent to **-35.73%**.

Vimedimex Medi - Pharma Joint Stock Company would like to report and explain the fluctuation of over 10% in Business Performance Results on the audited Separate Financial Statements and Consolidated Financial Statements of 2024 compared to the same period in 2023. Vimedimex Medi - Pharma Joint Stock Company commits that the above information is true./.

Best regards!

**Recipients:**

- As above;
- Board of Directors (for report);
- Archive: Clerical./.

**VIMEDIMEX MEDI - PHARMA JOINT STOCK  
COMPANY**



*[Handwritten signature]*  
**TỔNG GIÁM ĐỐC**  
*Trần Mỹ Linh*